Advertisement
Singapore markets closed
  • Straits Times Index

    3,177.89
    -9.77 (-0.31%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,814.76
    -62.29 (-0.79%)
     
  • Bitcoin USD

    64,669.84
    +3,301.10 (+5.38%)
     
  • CMC Crypto 200

    1,329.22
    +16.60 (+1.26%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,398.10
    +0.10 (+0.00%)
     
  • Crude Oil

    82.87
    +0.14 (+0.17%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,549.13
    +4.37 (+0.28%)
     
  • Jakarta Composite Index

    7,083.23
    -83.58 (-1.17%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

BioMarin Pharmaceutical and Its Promising Research Pipeline

BioMarin Pharmaceutical and Its Promising Research Pipeline

Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).